Publications by authors named "Andrew Zolopa"

Claim this Profile
W
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV.
Jeff Berko, Peter Mazonson, Duncan Short, Maile Karris, Lynsay Ehui, Andrew Zolopa

Antivir Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel, Andrew Zolopa

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Eva Fernvik, Juan Sierra Madero, Nuria Espinosa, Roberto Gulminetti, Debbie Hagins, Andrew Zolopa

J Acquir Immune Defic Syndr· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Number of Sexual Partners and Patient-Reported Outcomes Among Men Age 50+ with HIV.
Peter Mazonson, Jeff Berko, Erik Lowman, Bruce Gilliam, Toyin Nwafor, Andrew Zolopa

AIDS Res Hum Retroviruses· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Andrew R Zolopa

Open Forum Infect Dis· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
M Keith Rawlings, Emilio Letang, Romina Quercia, Richard Grove, Ralph DeMasi, Andrew Zolopa

Open Forum Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Resilience Among Older People Living with HIV.
Jeff Berko, Peter Mazonson, Theoren Loo, Philip Grant, Andrew Zolopa

AIDS Behav· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies.
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Andrew Zolopa

HIV Res Clin Pract· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Andrew R Zolopa

AIDS· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loneliness among older adults living with HIV: the "older old" may be less lonely than the "younger old".
Peter Mazonson, Jeff Berko, Theoren Loo, Mark Kane, Andrew Zolopa

AIDS Care· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Pain and Pain Medication Use with Multiple Characteristics of Older People Living with HIV.
Maile Y Karris, Jeff Berko, Peter D Mazonson, Theoren M Loo, Frank Spinelli, Andrew Zolopa

AIDS Res Hum Retroviruses· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
James Demarest, Mark Underwood, Marty St Clair, David Dorey, Dannae Brown, Andrew Zolopa

AIDS Res Hum Retroviruses· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
Sean E Collins, Philip M Grant, Francois Uwinkindi, Annie Talbot, Eric Seruyange, Andrew Zolopa

Open Forum Infect Dis· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Mina C Hosseinipour, Gregory P Bisson, Sachiko Miyahara, Xin Sun, Agnes Moses, Andrew Zolopa

Lancet· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in the outcomes of end-stage renal disease secondary to human immunodeficiency virus-associated nephropathy.
Sarah Razzak Chaudhary, Biruh T Workeneh, Maria E Montez-Rath, Andrew R Zolopa, Paul E Klotman

Nephrol Dial Transplant· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Paul E Sax, Andrew Zolopa, Indira Brar, Richard Elion, Roberto Ortiz

J Acquir Immune Defic Syndr· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender inequality and HIV transmission: a global analysis.
Eugene T Richardson, Sean E Collins, Tiffany Kung, James H Jones, Khai Hoan Tram, Andrew R Zolopa

J Int AIDS Soc· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.
Philip M Grant, Lauren Komarow, Alejandro Sanchez, Fred R Sattler, David M Asmuth, Andrew R Zolopa

HIV Clin Trials· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.
Emily C Liang, Lindsay Sceats, Nicholas L Bayless, Dara M Strauss-Albee, Jessica Kubo, Andrew R Zolopa

J Virol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.
Adriana Weinberg, Ronald Bosch, Kara Bennett, Adriana Tovar-Salazar, Constance A Benson, Andrew Zolopa

J Acquir Immune Defic Syndr· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Martin Markowitz, Andrew Zolopa, Kathleen Squires, Peter Ruane, Dion Coakley

J Antimicrob Chemother· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.
David A Wohl, Calvin Cohen, Joel E Gallant, Anthony Mills, Paul E Sax, Andrew Zolopa

J Acquir Immune Defic Syndr· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations.
Eugene T Richardson, Philip M Grant, Andrew R Zolopa

Antiviral Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
Philip M Grant, Camlin Tierney, Chakra Budhathoki, Eric S Daar, Paul E Sax, Andrew R Zolopa

HIV Clin Trials· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beta-glucan for Pneumocystis pneumonia diagnosis in persons with AIDS: authors' reply.
Brian R Wood, Lauren Komarow, Andrew R Zolopa, Malcolm A Finkelman, William G Powderly

AIDS· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis